EGFR is a transmembrane receptor tyrosine kinase with a crucial role in CRC development and progression, being, therefore, an important target for therapy by administration of EGFR monoclonal antibodies or tyrosine kinase inhibitors (153). The gene discussed is EGFR; the disease is colorectal carcinoma.